Compare CACC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CACC | DYN |
|---|---|---|
| Founded | 1972 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 4.8B |
| IPO Year | 1996 | 2020 |
| Metric | CACC | DYN |
|---|---|---|
| Price | $570.54 | $26.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $505.00 | $37.00 |
| AVG Volume (30 Days) | 110.4K | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.00 | N/A |
| EPS | ★ 25.04 | N/A |
| Revenue | ★ $2,317,200,000.00 | N/A |
| Revenue This Year | $91.73 | N/A |
| Revenue Next Year | $3.58 | N/A |
| P/E Ratio | $22.89 | ★ N/A |
| Revenue Growth | ★ 7.16 | N/A |
| 52 Week Low | $401.90 | $11.65 |
| 52 Week High | $668.86 | $27.31 |
| Indicator | CACC | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 57.40 |
| Support Level | $535.20 | $16.55 |
| Resistance Level | $621.52 | $26.62 |
| Average True Range (ATR) | 18.61 | 1.11 |
| MACD | 0.31 | -0.18 |
| Stochastic Oscillator | 34.54 | 57.23 |
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.